Characterization of low-density lipoprotein uptake by murine macrophages exposed to Chlamydia pneumoniae

Microbes and Infection

Volumn 1, Issue 6, 1999, Pages 409-418

  Kalayoglu, Murat V ^a   Miranpuri, Gurwattan S ^a   Golenbock, Douglas T ^b   Byrne, Gerald I ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b BOSTON MEDICAL CENTER   (United States)

Author keywords

Atherosclerosis; Chlamydia pneumoniae; Macrophage

Indexed keywords

ANTIOXIDANT; CARBOCYANINE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL CELL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CELL MEMBRANE TRANSPORT; CELL TRANSFORMATION; CHLAMYDOPHILA PNEUMONIAE; CONCENTRATION RESPONSE; CONTROLLED STUDY; FOAM CELL; LIPID OXIDATION; LIPOPROTEIN METABOLISM; MACROPHAGE; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALIA; CHLAMYDIA; CHLAMYDOPHILA PNEUMONIAE; MURINAE; RICKETTSIALES;

EID: 0032696264     PISSN: 12864579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1286-4579(99)80044-6     Document Type: Article

References (65)

1. Association A.H. Statistics NCfH. Heart and stroke facts: (1996) statistical supplement. American Heart Association. 1996.
2. Braunwald E. Shattuck lecture - cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N. Engl. J. M. 337:1997;1360-1369.
3. Stary H. Evolution and progression of atherosclerotic lesions in coronary arteries of children and young adults. Arteriosclerosis. 9:1989;19-32.
4. Stary H.C., Blankenhorn D.H., Chandler A.B., Glagov S., Insull W. Jr., Richardson M., et al. A definition of the intima of human arteries and of its atherosclerosis-prone regions. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 85:1992;391-405.
5. Stary H.C., Chandler A.B., Glagov S., Guyton J.R., Insull W., J R., Rosenfeld M.E., et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 89:1994;2462-2478.
6. Stary H.C., Chandler A.B., Dinsmore R.E., Fuster V., Glagov S., Insull W. Jr. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 92:1995;1355-1374.
7. Libby P., Clinton S. The role of macrophages in atherogenesis. Curr. Opin. Lipidol. 4:1993;355-363.
8. Goldstein J.L., Brown M.S. The low-density lipoprotein pathway and its relation to atherosclerosis. Annu. Rev. Biochem. 46:1977;897-930.
9. Goldstein J.L., Basu S.K., Brown M.S. Receptor-mediated endocytosis of low-density lipoprotein in cultured cells. Methods Enzymol. 98:1983;241-260.
10. Brown M.S., Goldstein J.L. Receptor-mediated endocytosis: insights from the lipoprotein receptor system. Proc. Natl. Acad. Sci. USA. 76:1979;3330-3337.
11. Brown M., J G. Lipoprotein metabolism in the macrophage. Annu. Rev. Biochem. 52:1983;223-261.
12. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J. Biol. Chem. 272:1997;20963-20966.
13. Steinberg D. Oxidative modification of LDL and atherogenesis. Circulation. 95:1997;1062-1071.
14. Goldstein J., Ho Y., Basu S., Brown M. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc. Natl. Acad. Sci. USA. 76:1979;333-337.
15. Wang X., Bucala R., Milne R. Epitopes close to the apolipoprotein B low density lipoprotein receptor-binding site are modified by advanced glycation end products. Proc. Natl. Acad. Sci. USA. 95:1998;7-7643.
16. Heinecke J.W. Mechanisms of oxidative damage of low density lipoprotein in human atherosclerosis. Curr. Opin. Lipidol. 8:1997;268-274.
17. Aviram M., Oiknine J. Involvement of second messangers in lipopolysaccharide stimulation of low density lipoprotein uptake by macrophages. Isr. J. Med. Sci. 30:1994;503-506.
18. Lopes-Virella M. Interactions between bacterial lipopolysaccharides and serum lipoproteins and their possible role in coronary heart disease. Eur. Heart J. 14:1993;118-124.
19. Oiknine J., Aviram M. Increased susceptibility to activation and increased uptake of low density lipoprotein by cholesterol-loaded macrophages. Arterioscler. Thromb. 12:1992;745-753.
20. Lopes-Virella M., Klein R. HC, Low density lipoprotein metabolism in human macrophages stimulated with microbial or microbial-related products. Arteriosclerosis. 7:1987;176-184.
21. Funk J., Feingold K., Moser A., Grunfeld C. Lipopolysaccharide stimulation of RAW 264.7 macrophages induces lipid accumulation and foam cell formation. Atherosclerosis. 98:1993;67-82.
22. Khoo J.C., Miller E., McLoughlin P., Steinberg D. Enhanced macrophage uptake of low density lipoprotein after self-aggregation. Arteriosclerosis. 8:1988;348-358.
23. Lopes-Virella M.F., Binzafar N., Rackley S., Takei A., LaVia M., Virella G. The uptake of LDL-IC by human macrophages: predominant involvement of the Fc gamma RI receptor. Atherosclerosis. 135:1997;161-170.
24. Mehta J.L., Saldeen T.G., Rand K. Interactive role of infection, inflammation and traditional risk factors in atherosclerosis and coronary artery disease. J. Am. Coll. Cardiol. 31:1998;1217-1225.
25. Mattila K.J., Valtonen V.V., Nieminen M.S., Asikainen S. Role of infection as a risk factor for atherosclerosis, myocardial infarction, and stroke. Clin. Infect. Dis. 26:1998;719-734.
26. Kuo C., Campbell L.A. Is infection with Chlamydia pneumoniae a causative agent in atherosclerosis? Mol. Med. Today. 4:1998;426-430.
27. Saikku P. Chlamydia pneumoniae and atherosclerosis - an update. Scand. J. Infect. Dis. 104:1997;53-56.
28. Thom D.H., Grayston J.T., Siscovick D.S., Wang S.P., Weiss N.S., Daling J.R. Association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary artery disease. JAMA. 268:1992;68-72.
29. Saikku P., Leinonen M., Tenkanen L., Linnanmaki E., Ekman M.R., Manninen V., Et A.L. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann. Intern. M. 116:1992;273-278.
30. Shor A., Kuo C.C., Patton D.L. Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques. S. Afr. Med. J. 82:1992;158-161.
31. Kuo C.C., Grayston J.T., Campbell L.A., Goo Y.A., Wissler R.W., Benditt E.P. Chlamydia pneumoniae (TWAR) in coronary arteries of young adults (15-34 years old). Proc. Natl. Acad. Sci. USA. 92:1995;6911-6914.
32. Muhlestein J.B., Hammond E.H., Carlquist J.F., Radicke E., Thomson M.J., Karagounis L.A., Et A.L. Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease. J. Am. Coll. Cardiol. 27:1996;1555-1561.
33. Ramirez J.A. Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. The Chlamydia pneumoniae/Atherosclerosis Study Group. Ann. Intern. M. 125:1996;979-982.
34. Jackson L.A., Campbell L.A., Kuo C.C., Rodriguez D.I., Lee A., Grayston J.T. Isolation of Chlamydia pneumoniae from a carotid endarterectomy specimen. J. Infect. Dis. 176:1997;292-295.
35. Moazed T.C., Kuo C., Grayston J.T., Campbell L.A. Murine models of Chlamydia pneumoniae infection and atherosclerosis. J. Infect. Dis. 175:1997;883-890.
36. Fong I.W., Chiu B., Viira E., Fong M.W., Jang D., Mahony J. Rabbit model for Chlamydia pneumoniae infection. J. Clin. Microbiol. 35:1997;48-52.
37. Laitinen K., Laurila A., Pyhala L., Leinonen M., Saikku P. Chlamydia pneumoniae infection induces inflammatory changes in the aortas of rabbits. Infect. Immun. 65:1997;4832-4835.
38. Muhlestein J.B., Anderson J.L., Hammond E.H., Zhao L., Trehan S., Schwobe E.P., Et A.L. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation. 97:1998;633-636.
39. Gupta S., Leatham E.W., Carrington D., Mendall M.A., Kaski J.C., Camm A.J. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation. 96:1997;404-407.
40. Gurfinkel E., Bozovich G., Daroca A., Beck E., Mautner B. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. ROXIS Study Group. Lancet. 350:1997;404-407.
41. Kaukoranta-Tolvanen S.S., Teppo A.M., Laitinen K., Saikku P., Linnavuori K., Leinonen M. Growth of Chlamydia pneumoniae in cultured human peripheral blood mononuclear cells and induction of a cytokine response. Microb. Pathog. 21:1996;215-221.
42. Godzik K.L., Oqbrien E.R., Wang S.K., Kuo C.C. In vitro susceptibility of human vascular wall cells to infection with Chlamydia pneumoniae. J. Clin. Microbiol. 33:1995;2411-2414.
43. Gaydos C.A., Summersgill J.T., Sahney N.N., Ramirez J.A., Quinn T.C. Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells. Infect. Immun. 64:1996;1614-1620.
44. Kalayoglu M., Byrne G. A Chlamydia pneumoniae component that induces macrophage foam cell formation is chlamydial lipopolysaccharide. Infect. Immun. 66:1998;5067-5072.
45. Kalayoglu M.V., Byrne G.I. Induction of macrophage foam cell formation by Chlamydia pneumoniae. J. Infect. Dis. 177:1998;725-729.
46. Innerarity T.L., Pitas R.E., Mahley R.W. Lipoprotein-receptor interactions. Methods Enzymol. 129:1986;542-565.
47. Redgrave T., Roberts D., West C. Separation of plasma lipoproteins by density-gradient ultracentrifugation. Anal. Biochem. 65:1975;42-49.
48. Lynch S.M., Frei B. Mechanisms of copper- and iron-dependent oxidative modification of human low density lipoprotein. J. Lipid. Res. 34:1993;1745-1753.
49. Caldwell H., Kromhout J., Schachter J. Purification and partial characterization of the major outer membrane protein of Chlamydia trachomatis. Infect. Immun. 31:1981;1161-1176.
50. Galanos C., Luderitz O., Westphal O. A new method for the extraction of R lipopolysaccharides. Eur. J. Biochem. 9:1969;245-249.
51. Ingalls R., Rice P., Qureshi N., Takayama K., Shin-Lin J., Golenbock D. The inflammatory cytokine response to Chlamydia trachomatis infection is endotoxin mediated. Infect. Immun. 63:1995;3125-3130.
52. Qureshi N., Mascagni P., Ribi E., Takayama K. Monophosphoryl lipid A obtained from lipopolysaccharides of Salmonella minnesota R595. J. Biol. Chem. 260:1985;5271-5278.
53. Teupser D., Thiery J., Walli A.K., Seidel D. Determination of LDL- and scavenger-receptor activity in adherent and non-adherent cultured cells with a new single-step fluorometric assay. Biochim. Biophys. Acta. 1303:1996;193-198.
54. McDowell M., Lucas D., Nicolet C., Paulnock D. Differential utilization of interferon-gamma responsive elements in two maturationally distinct macrophage cell lines. J. Immunol. 155:1995;4933-4938.
55. Calvo D., Gomez-Coronado D., Suarez Y., Lasuncion M., Vega M. Human CD36 is a high affinity receptor for the native lipoproteins HDL, LDL and VLDL. J. Lipid. Res. 39:1998;777-788.
56. Acton S.L., Scherer P.E., Lodish H.F., Krieger M. Expression cloning of SR-BI, a CD36-related class B scavenger receptor. J. Biol. Chem. 269:1994;21003-21009.
57. Calvo D., Gomez-Coronado D., Lasuncion M. Vega M, CLA-1 is an 85-kD plasma membrane glycoprotein that acts as a high-affinity receptor for both native (HDL, LDL, and VLDL) and modified (OxLDL and AcLDL) lipoproteins. Arterioscler. Thromb. Vasc. Biol. 17:1997;2341-2349.
58. Fuki I.V., Kuhn K.M., Lomazov I.R., Rothman V.L., Tuszynski G.P., Iozzo R.V., Et A.L. The syndecan family of proteoglycans. Novel receptors mediating internalization of atherogenic lipoproteins in vitro. J. Clin. Invest. 100:1997;1611-1622.
59. Williams K.J., Fuki I.V. Cell-surface heparan sulfate proteoglycans: dynamic molecules mediating ligand catabolism. Curr. Opin. Lipidol. 8:1997;253-262.
60. Rigotti A., Acton S.L., Krieger M. The class B scavenger receptors SR-BI and CD36 are receptors for anionic phospholipids. J. Biol. Chem. 270:1995;16221-16224.
61. Yamada Y., Doi T., Hamakubo T., Kodama T. Scavenger receptor family proteins: roles for atherosclerosis, host defence and disorders of the central nervous system. Cell Mol. Life Sci. 54:1998;628-640.
62. Yeaman C., Rapraeger A.C. Membrane-anchored proteoglycans of mouse macrophages: P388D1 cells express a syndecan-4-like heparan sulfate proteoglycan and a distinct chondroitin sulfate form. J. Cell. Physiol. 157:1993;413-425.
63. Yeaman C., Rapraeger A.C. Post-transcriptional regulation of syndecan-1 expression by cAMP in peritoneal macrophages. J. Cell. Biol. 122:1993;941-950.
64. Ross R. Atherosclerosis is an inflammatory disease. N. Eng. J. M. 340:1999.
65. Villiers W.J., Smith J.D., Miyata M., Dansky H.M., Darley E., Gordon S. Macrophage phenotype in mice deficient in both macrophage colony stimulating factor (Op) and apolipoprotein E. Arterioscler. Thromb. Vasc. Biol. 18:1998;631-640.